Brokerages Set Humana Inc. (NYSE:HUM) Price Target at $285.68

Shares of Humana Inc. (NYSE:HUM) have received a consensus rating of “Hold” from the twenty-four ratings firms that are presently covering the company, Marketbeat Ratings reports. Nineteen research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $285.68.

A number of equities analysts have recently issued reports on the stock. TD Cowen increased their price objective on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research note on Monday, November 4th. JPMorgan Chase & Co. dropped their target price on Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 18th. Royal Bank of Canada reissued an “outperform” rating and issued a $283.00 price target on shares of Humana in a research report on Wednesday, February 12th. Bank of America raised Humana from an “underperform” rating to a “neutral” rating and raised their price objective for the company from $247.00 to $308.00 in a research report on Wednesday, November 6th. Finally, Piper Sandler lifted their price objective on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th.

Humana Stock Down 1.6 %

Shares of HUM opened at $255.06 on Monday. The firm has a fifty day moving average price of $270.12 and a 200-day moving average price of $288.06. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $30.77 billion, a P/E ratio of 25.63, a P/E/G ratio of 2.05 and a beta of 0.56. Humana has a 12-month low of $213.31 and a 12-month high of $406.46.

Humana (NYSE:HUM) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Equities research analysts expect that Humana will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.39%. The ex-dividend date is Friday, March 28th. Humana’s payout ratio is 35.58%.

Insider Buying and Selling

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.32% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Humana

Several institutional investors have recently made changes to their positions in the company. Pinnacle Wealth Management Advisory Group LLC grew its position in Humana by 3.6% during the fourth quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider’s stock valued at $272,000 after buying an additional 37 shares during the period. Atlas Brown Inc. boosted its stake in shares of Humana by 0.6% during the 4th quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock worth $1,611,000 after acquiring an additional 38 shares in the last quarter. Moors & Cabot Inc. boosted its stake in shares of Humana by 2.5% during the 3rd quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock worth $519,000 after acquiring an additional 40 shares in the last quarter. Mather Group LLC. grew its position in shares of Humana by 21.0% during the 4th quarter. Mather Group LLC. now owns 236 shares of the insurance provider’s stock valued at $60,000 after acquiring an additional 41 shares during the period. Finally, Capital Advisors Ltd. LLC increased its stake in shares of Humana by 26.1% in the 4th quarter. Capital Advisors Ltd. LLC now owns 208 shares of the insurance provider’s stock valued at $53,000 after purchasing an additional 43 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.